Warfarin: An inconvenient truth

Melina Gattellari, John Worthington, Nicholas Zwar

Research output: Contribution to journalEditorialResearch

6 Citations (Scopus)

Abstract

In 1989, the Copenhagen AFASAK study reported results from the first randomized, placebo-controlled trial evaluating adjusted-dose warfarin and aspirin in the prevention of stroke for nonvalvular atrial fibrillation (NVAF). Like the 5 randomized, placebo-controlled trials that came after it, the Copenhagen AFASAK study demonstrated a reduction in embolic events in patients taking warfarin. Today, the weight of evidence from 18 trials comparing warfarin with either placebo or antiplatelet drugs overwhelmingly favors the use of warfarin for stroke prevention in NVAF.
Original languageEnglish
Pages (from-to)5-7
Number of pages3
JournalStroke
Volume40
Issue number1
DOIs
Publication statusPublished - 1 Jan 2009
Externally publishedYes

Fingerprint

Warfarin
Placebos
Atrial Fibrillation
Randomized Controlled Trials
Stroke
Platelet Aggregation Inhibitors
Aspirin
Weights and Measures

Cite this

Gattellari, Melina ; Worthington, John ; Zwar, Nicholas. / Warfarin : An inconvenient truth. In: Stroke. 2009 ; Vol. 40, No. 1. pp. 5-7.
@article{02515ff95fd6456e9dc03027b6aa355a,
title = "Warfarin: An inconvenient truth",
abstract = "In 1989, the Copenhagen AFASAK study reported results from the first randomized, placebo-controlled trial evaluating adjusted-dose warfarin and aspirin in the prevention of stroke for nonvalvular atrial fibrillation (NVAF). Like the 5 randomized, placebo-controlled trials that came after it, the Copenhagen AFASAK study demonstrated a reduction in embolic events in patients taking warfarin. Today, the weight of evidence from 18 trials comparing warfarin with either placebo or antiplatelet drugs overwhelmingly favors the use of warfarin for stroke prevention in NVAF.",
author = "Melina Gattellari and John Worthington and Nicholas Zwar",
year = "2009",
month = "1",
day = "1",
doi = "10.1161/STROKEAHA.108.527903",
language = "English",
volume = "40",
pages = "5--7",
journal = "Stroke",
issn = "0039-2499",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

Gattellari, M, Worthington, J & Zwar, N 2009, 'Warfarin: An inconvenient truth' Stroke, vol. 40, no. 1, pp. 5-7. https://doi.org/10.1161/STROKEAHA.108.527903

Warfarin : An inconvenient truth. / Gattellari, Melina; Worthington, John; Zwar, Nicholas.

In: Stroke, Vol. 40, No. 1, 01.01.2009, p. 5-7.

Research output: Contribution to journalEditorialResearch

TY - JOUR

T1 - Warfarin

T2 - An inconvenient truth

AU - Gattellari, Melina

AU - Worthington, John

AU - Zwar, Nicholas

PY - 2009/1/1

Y1 - 2009/1/1

N2 - In 1989, the Copenhagen AFASAK study reported results from the first randomized, placebo-controlled trial evaluating adjusted-dose warfarin and aspirin in the prevention of stroke for nonvalvular atrial fibrillation (NVAF). Like the 5 randomized, placebo-controlled trials that came after it, the Copenhagen AFASAK study demonstrated a reduction in embolic events in patients taking warfarin. Today, the weight of evidence from 18 trials comparing warfarin with either placebo or antiplatelet drugs overwhelmingly favors the use of warfarin for stroke prevention in NVAF.

AB - In 1989, the Copenhagen AFASAK study reported results from the first randomized, placebo-controlled trial evaluating adjusted-dose warfarin and aspirin in the prevention of stroke for nonvalvular atrial fibrillation (NVAF). Like the 5 randomized, placebo-controlled trials that came after it, the Copenhagen AFASAK study demonstrated a reduction in embolic events in patients taking warfarin. Today, the weight of evidence from 18 trials comparing warfarin with either placebo or antiplatelet drugs overwhelmingly favors the use of warfarin for stroke prevention in NVAF.

UR - http://www.scopus.com/inward/record.url?scp=60549093415&partnerID=8YFLogxK

U2 - 10.1161/STROKEAHA.108.527903

DO - 10.1161/STROKEAHA.108.527903

M3 - Editorial

VL - 40

SP - 5

EP - 7

JO - Stroke

JF - Stroke

SN - 0039-2499

IS - 1

ER -